Val­ne­va re­ceives first chikun­gun­ya vac­cine ap­proval af­ter two month de­lay to FDA re­view

Val­ne­va re­ceived the first reg­u­la­to­ry ap­proval for a chikun­gun­ya virus vac­cine with an FDA ac­cel­er­at­ed nod on Thurs­day night.

The green light marks a key win for the Eu­ro­pean biotech, which will get more than a year’s head start on po­ten­tial com­peti­tor Bavar­i­an Nordic and could snag about $100 mil­lion by sell­ing the pri­or­i­ty re­view vouch­er that it gets as part of the ap­proval. It al­so serves as a boon to Val­ne­va as the com­pa­ny works through hur­dles with an­oth­er of its late-stage in­ves­ti­ga­tion­al vac­cines for Ly­me dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER